Combunox's Future At Forest May Depend On Success Of New Trial Program
This article was originally published in The Pink Sheet Daily
Executive Summary
The future of Forest's combination pain therapy Combunox (oxycodone/ibuprofen)could depend on the success of a new product trial program launched in late September, the company suggested